Information Provided By:
Fly News Breaks for January 10, 2020
CHMA
Jan 10, 2020 | 11:26 EDT
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $11 price target on Chiasma following the company's NDA submission for Mycapssa on December 26 based on positive Phase III OPTIMAL data. Tenthoff said he is confident in Mycapssa approval in the U.S., adding that manufacturing preparation is underway ahead of launch. The analyst added that Chiasma remains on-track to report top-line data from Phase III MPOWERED study in Europe in Q4 to support EMA approval.
News For CHMA From the Last 2 Days
There are no results for your query CHMA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.